These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24596468)

  • 41. Cost of Bleeding-related Episodes in Adult Patients With Primary Immune Thrombocytopenia: A Population-based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States.
    Lin J; Zhang X; Li X; Chandler D; Altomare I; Wasser JS; Cetin K
    Clin Ther; 2017 Mar; 39(3):603-609.e1. PubMed ID: 28190600
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
    Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
    J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
    [No Abstract]   [Full Text] [Related]  

  • 43. Commercial claims costs related to health care resource use associated with a diagnosis of peanut allergy.
    Shaker M; Chalil JM; Tran O; Vlahiotis A; Shah H; King T; Green TD; Greenhawt M
    Ann Allergy Asthma Immunol; 2020 Apr; 124(4):357-365.e1. PubMed ID: 31954759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.
    Burke JP; Hunsche E; Régulier E; Nagao M; Buzinec P; Drake Iii W
    Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
    Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
    World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database.
    Walsh JA; Song X; Kim G; Park Y
    Rheumatol Ther; 2018 Dec; 5(2):463-474. PubMed ID: 30121826
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of minimally invasive sacroiliac joint fusion.
    Cher DJ; Frasco MA; Arnold RJ; Polly DW
    Clinicoecon Outcomes Res; 2016; 8():1-14. PubMed ID: 26719717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and 6-month effectiveness of minimally invasive sacroiliac joint fusion: a prospective study.
    Duhon BS; Cher DJ; Wine KD; Lockstadt H; Kovalsky D; Soo CL
    Med Devices (Auckl); 2013; 6():219-29. PubMed ID: 24363562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two-year comprehensive medical management of degenerative lumbar spine disease (lumbar spondylolisthesis, stenosis, or disc herniation): a value analysis of cost, pain, disability, and quality of life: clinical article.
    Parker SL; Godil SS; Mendenhall SK; Zuckerman SL; Shau DN; McGirt MJ
    J Neurosurg Spine; 2014 Aug; 21(2):143-9. PubMed ID: 24785973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.
    Wang SX; Ganguli AX; Bodhani A; Medema JK; Reichmann WM; Macaulay D
    J Med Econ; 2017 Dec; 20(12):1299-1306. PubMed ID: 28880733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MIS Fusion of the SI Joint: Does Prior Lumbar Spinal Fusion Affect Patient Outcomes?
    Rudolf L
    Open Orthop J; 2013; 7():163-8. PubMed ID: 23730380
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of transforaminal lumbar interbody fusion for Grade I degenerative spondylolisthesis.
    Adogwa O; Parker SL; Davis BJ; Aaronson O; Devin C; Cheng JS; McGirt MJ
    J Neurosurg Spine; 2011 Aug; 15(2):138-43. PubMed ID: 21529203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.
    Coyne KS; Paramore C; Grandy S; Mercader M; Reynolds M; Zimetbaum P
    Value Health; 2006; 9(5):348-56. PubMed ID: 16961553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Minimally invasive sacroiliac joint fusion secondary to lumbosacral fusion: Clinical and functional results at 2years of follow-up.
    Bricard R; Pelletier Y; Allia J; Raffaelli A; Gonzalez JF; de Dompsure R; Bronsard N
    Orthop Traumatol Surg Res; 2024 Apr; ():103892. PubMed ID: 38648887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sacroiliac joint fusion health care cost comparison prior to and following surgery: an administrative claims analysis.
    Buysman EK; Halpern R; Polly DW
    Clinicoecon Outcomes Res; 2018; 10():643-651. PubMed ID: 30410374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment, Resource Use and Costs Among Pediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas.
    Yang X; Desai K; Agrawal N; Mirchandani K; Chatterjee S; Sarpong E; Sen S
    Pediatric Health Med Ther; 2020; 11():421-428. PubMed ID: 33117057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incremental Costs Associated with Length of Hospitalization Due to Viral Pneumonia: Impact of Intensive Care and Economic Implications of Reducing the Length of Stay in the Era of COVID-19.
    Wu N; Kuznik A; Wang D; Moretz C; Xi A; Kumar S; Hamilton L
    Clinicoecon Outcomes Res; 2020; 12():723-731. PubMed ID: 33293840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lumbar fusion surgery for degenerative conditions is associated with significant resource and narcotic use 2 years postoperatively in the commercially insured: a medical and pharmacy claims study.
    Mino DE; Munterich JE; Castel LD
    J Spine Surg; 2017 Jun; 3(2):141-148. PubMed ID: 28744493
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A 2-Year Cost Analysis of Maximum Nonoperative Treatments in Patients With Symptomatic Lumbar Stenosis or Spondylolisthesis That Ultimately Required Surgery.
    Adogwa O; Davison MA; Lilly DT; Vuong VD; Desai SA; Moreno J; Cheng J; Bagley C
    Global Spine J; 2019 Jun; 9(4):424-433. PubMed ID: 31218202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.
    Maiese EM; Evans KA; Chu BC; Irwin DE
    Am Health Drug Benefits; 2018 Feb; 11(1):39-46. PubMed ID: 29692879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.